Posts Tagged ‘dry amd’
Expanding excellence in vision care: Welcoming Tanya Alvares to John Rose Eye Care, Kingston Upon Thames, London
At John Rose Eye Care, we continue to redefine clinical excellence in independent optometry by expanding our world-class team and clinical services. We are proud to welcome two esteemed professionals to our Kingston Upon Thames London clinic: Tanya Alvares, BSc (Hons) MCOptom and Dr. Zimar Sivardeen, MBA, PhD, FBCLA, FCOptom, FEAOO. These highly regarded Optometrists …
Read MoreNon-Invasive Dry AMD Therapy available in Kingston upon Thames, London
A breakthrough in photobiomodulation therapy for eye health — at John Rose Eye Care If you or a loved one has been diagnosed with dry Age-related Macular Degeneration (AMD) — or you are at risk and looking for proactive, private eye care in Richmond, Barnes, Surbiton, London or across Surrey — we invite you…
Read MoreValeda LDS – the first and ONLY FDA-authorised treatment for dry AMD to improve vision!
A New Era in Macular Degeneration Care – Safe, Effective and Non-Invasive 🔹 Key Highlights ✅ Rigorous Clinical Trials: LightSite II and LightSite III confirmed effectiveness. ✅ FDA-Approved (November 2024): The first and only treatment using photobiomodulation (PBM) for AMD to receive FDA approval. FDA Approval Announcement ✅Proven Track Record: Over 750,000 treatments performed worldwide…
Read MoreDiscover the Latest in Dry AMD Treatment with John Rose Optometrist
Join optometrist John Rose in conversation with journalist Angela Young as they discuss the FDA-approved Valeda Light Delivery System (LDS) treatment for Dry Age-Related Macular Degeneration (AMD). Hear directly from John and Alita, one of our AMD patients, about how this innovative therapy works and their personal experience with Valeda. 🎧✨ Listen to the…
Read MoreThe Valeda LDS treatment for dry AMD is now FDA approved
LumiThera has received U.S. FDA authorisation to market its Valeda® Light Delivery System, the first FDA-approved treatment for vision loss due to dry age-related macular degeneration (AMD). The non-invasive photobiomodulation (PBM) device demonstrated improved visual acuity and safety over 24 months in the pivotal LIGHTSITE III trial, with results showing that Valeda slowed disease progression…
Read MoreJohn Rose Features on the “Talking about ‘degeneration” Apple Podcast
Shining a Light on the Future of Photobiomodulation for AMD Listen to John Rose’s interview featured after Dr Clark Tedford, founder of Lumithera Inc in the “Talking about ‘degeneration” Podcast by Angela Young – Cambridge Podcasts. John discusses the Valeda LDS treatment overview for dry AMD patients. John is the world’s first optometrist to offer…
Read MoreEnhancing AMD Care with AI – Q & A with John Rose Optometrist, Kingston
AMD eye diagnostics and AI At John Rose Eye Care in Kingston upon Thames we are committed to leading the way in age-related macular degeneration (AMD) care, by being the first Optometric Practice in the UK to adopt the RetinSight AI software. This innovative technology is not just about leveraging AI; it’s about significantly enhancing…
Read MoreValeda LDS, the treatment for patients suffering from Dry Age-Related Macular Degeneration
Managing Dry Macular Degeneration (AMD) Age-Related Macular Degeneration is a gradual loss of vision that progresses with age. It normally affects central vision, particularly contrast sensitivity, dark adaptation, colour vision and depth perception – changes that influence performance and experience of day-to-day tasks and hobbies such as reading, driving, watching TV, painting etc. Early stages…
Read More